Novartis AG $NVS Shares Bought by May Hill Capital LLC

May Hill Capital LLC grew its position in Novartis AG (NYSE:NVS) by 49.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,274 shares of the company’s stock after acquiring an additional 2,084 shares during the period. May Hill Capital LLC’s holdings in Novartis were worth $759,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Novartis by 76.5% in the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Novartis by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 6,524 shares of the company’s stock valued at $727,000 after buying an additional 1,500 shares during the period. Spire Wealth Management boosted its stake in shares of Novartis by 17.2% in the first quarter. Spire Wealth Management now owns 3,032 shares of the company’s stock valued at $338,000 after buying an additional 446 shares in the last quarter. Bessemer Group Inc. grew its holdings in Novartis by 10.9% during the first quarter. Bessemer Group Inc. now owns 11,289 shares of the company’s stock worth $1,258,000 after acquiring an additional 1,105 shares during the period. Finally, Western Wealth Management LLC purchased a new position in Novartis in the first quarter worth $216,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Stock Performance

NYSE:NVS opened at $129.12 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $272.76 billion, a P/E ratio of 18.79, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64. The firm has a 50-day moving average price of $127.66 and a two-hundred day moving average price of $119.78. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55.

Wall Street Analyst Weigh In

NVS has been the topic of several research analyst reports. Jefferies Financial Group restated a “hold” rating on shares of Novartis in a research report on Monday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Wall Street Zen upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group reissued a “sell” rating and set a $118.00 price target (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $120.33.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.